BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16509569)

  • 1. Novel 1alpha,25-dihydroxyvitamin D3 analogues with the side chain at C12.
    González-Avión XC; Mouriño A; Rochel N; Moras D
    J Med Chem; 2006 Mar; 49(5):1509-16. PubMed ID: 16509569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.
    Tocchini-Valentini G; Rochel N; Wurtz JM; Moras D
    J Med Chem; 2004 Apr; 47(8):1956-61. PubMed ID: 15055995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 22-Alkyl-20-epi-1alpha,25-dihydroxyvitamin D3 compounds of superagonistic activity: syntheses, biological activities and interaction with the receptor.
    Yamamoto K; Inaba Y; Yoshimoto N; Choi M; DeLuca HF; Yamada S
    J Med Chem; 2007 Mar; 50(5):932-9. PubMed ID: 17298045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain.
    Shimizu M; Miyamoto Y; Kobayashi E; Shimazaki M; Yamamoto K; Reischl W; Yamada S
    Bioorg Med Chem; 2006 Jun; 14(12):4277-94. PubMed ID: 16503143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity of CD-ring modified 1alpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues.
    Verstuyf A; Verlinden L; van Etten E; Shi L; Wu Y; D'Halleweyn C; Van Haver D; Zhu GD; Chen YJ; Zhou X; Haussler MR; De Clercq P; Vandewalle M; Van Baelen H; Mathieu C; Bouillon R
    J Bone Miner Res; 2000 Feb; 15(2):237-52. PubMed ID: 10703925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first locked side-chain analogues of calcitriol (1alpha,25-dihydroxyvitamin D3) induce vitamin D receptor transcriptional activity.
    Pérez-García X; Rumbo A; Larriba MJ; Ordóñez P; Muñoz A; Mouriño A
    Org Lett; 2003 Oct; 5(22):4033-6. PubMed ID: 14572242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor.
    Väisänen S; Peräkylä M; Kärkkäinen JI; Uskokovic MR; Carlberg C
    Mol Pharmacol; 2003 Jun; 63(6):1230-7. PubMed ID: 12761332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of 16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs having side chains of different sizes.
    Takaku H; Miyamoto Y; Asami S; Shimazaki M; Yamada S; Yamamoto K; Udagawa N; DeLuca HF; Shimizu M
    Bioorg Med Chem; 2008 Feb; 16(4):1796-815. PubMed ID: 18032055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of five 19-nor-analogs of 1alpha,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains: implications for ligand binding and calcemic properties.
    Olivera CJ; Bula CM; Bishop JE; Adorini L; Manchand P; Uskokovic MR; Norman AW
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):99-106. PubMed ID: 15225754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 25-Dehydro-1alpha-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change.
    Bula CM; Bishop JE; Ishizuka S; Norman AW
    Mol Endocrinol; 2000 Nov; 14(11):1788-96. PubMed ID: 11075812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor ligands for osteoporosis.
    Cheskis BJ; Freedman LP; Nagpal S
    Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric catalytic ene-cyclization approach to 2-fluoro-19-nor-1,25-dihydroxyvitamin D(3) A-ring analog with significant transactivation activity.
    Mikami K; Ohba S; Ohmura H; Kubodera N; Nakagawa K; Okano T
    Chirality; 2001 Jul; 13(7):366-71. PubMed ID: 11400190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antagonist for the vitamin D receptor: vitamin D analogues with simple side chain structure.
    Sakamaki Y; Inaba Y; Yoshimoto N; Yamamoto K
    J Med Chem; 2010 Aug; 53(15):5813-26. PubMed ID: 20608741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives.
    Glebocka A; Sicinski RR; Plum LA; Clagett-Dame M; DeLuca HF
    J Med Chem; 2006 May; 49(10):2909-20. PubMed ID: 16686534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings.
    Verstuyf A; Verlinden L; Van Baelen H; Sabbe K; D'Hallewyn C; De Clercq P; Vandewalle M; Bouillon R
    J Bone Miner Res; 1998 Apr; 13(4):549-58. PubMed ID: 9556055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of 19-norvitamin D analogs having a fluoroethylidene group at the C-2 position.
    Kobayashi E; Shimazaki M; Miyamoto Y; Masuno H; Yamamoto K; DeLuca HF; Yamada S; Shimizu M
    Bioorg Med Chem; 2007 Feb; 15(3):1475-82. PubMed ID: 17110116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D receptor ligands: the impact of crystal structures.
    Carlberg C; Molnár F; Mouriño A
    Expert Opin Ther Pat; 2012 Apr; 22(4):417-35. PubMed ID: 22449247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functionalization at C-12 of 1alpha,25-dihydroxyvitamin D(3) strongly modulates the affinity for the vitamin D receptor (VDR).
    González-Avión XC; Mouriño A
    Org Lett; 2003 Jun; 5(13):2291-3. PubMed ID: 12816431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction.
    Eelen G; Verlinden L; Rochel N; Claessens F; De Clercq P; Vandewalle M; Tocchini-Valentini G; Moras D; Bouillon R; Verstuyf A
    Mol Pharmacol; 2005 May; 67(5):1566-73. PubMed ID: 15728261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural variants of the vitamin D analogue EB1089 reduce its ligand sensitivity and promoter selectivity.
    Quack M; Clarin A; Binderup E; Björkling F; Hansen CM; Carlberg C
    J Cell Biochem; 1998 Dec; 71(3):340-50. PubMed ID: 9831071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.